$64.30 Million in Sales Expected for Certara, Inc. (NASDAQ:CERT) This Quarter


Share on StockTwits

Brokerages expect Certara, Inc. (NASDAQ:CERT) to announce $64.30 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Certara’s earnings, with the lowest sales estimate coming in at $63.50 million and the highest estimate coming in at $65.09 million. The company is scheduled to announce its next quarterly earnings results on Thursday, June 3rd.

According to Zacks, analysts expect that Certara will report full-year sales of $281.09 million for the current fiscal year, with estimates ranging from $278.39 million to $285.20 million. For the next financial year, analysts anticipate that the company will post sales of $323.32 million, with estimates ranging from $317.85 million to $333.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Certara.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, March 3rd. The company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.06. The business had revenue of $64.60 million during the quarter, compared to analyst estimates of $61.31 million. The business’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.03) EPS.

A number of research firms recently weighed in on CERT. Bank of America began coverage on Certara in a report on Tuesday, January 5th. They issued a “buy” rating and a $41.00 price target for the company. Zacks Investment Research cut Certara from a “hold” rating to a “sell” rating in a report on Wednesday, March 24th. Credit Suisse Group began coverage on Certara in a report on Tuesday, January 5th. They issued a “neutral” rating and a $35.00 price target for the company. Jefferies Financial Group began coverage on Certara in a report on Tuesday, January 5th. They set a “hold” rating and a $33.00 target price for the company. Finally, William Blair reissued an “outperform” rating on shares of Certara in a report on Friday, March 5th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $36.40.

NASDAQ CERT traded down $0.26 during trading hours on Monday, reaching $26.63. The company’s stock had a trading volume of 604 shares, compared to its average volume of 686,166. Certara has a 1-year low of $24.58 and a 1-year high of $41.79. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.76. The firm has a 50-day moving average price of $30.55.

In other Certara news, major shareholder Avatar Parent L.P. Eqt sold 8,674,151 shares of the stock in a transaction that occurred on Monday, March 29th. The stock was sold at an average price of $24.12, for a total transaction of $209,220,522.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD purchased a new stake in shares of Certara in the fourth quarter valued at approximately $99,386,000. JPMorgan Chase & Co. purchased a new stake in shares of Certara in the fourth quarter valued at approximately $66,678,000. Janus Henderson Group PLC purchased a new stake in shares of Certara in the fourth quarter valued at approximately $40,076,000. BlackRock Inc. purchased a new stake in shares of Certara in the fourth quarter valued at approximately $35,205,000. Finally, Alliancebernstein L.P. purchased a new stake in shares of Certara in the fourth quarter valued at approximately $32,406,000.

Certara Company Profile

Certara Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development.

Recommended Story: Special Dividends

Get a free copy of the Zacks research report on Certara (CERT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Certara (NASDAQ:CERT)

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.